MA55206A - Polyribonucléotides circulaires et compositions pharmaceutiques associées - Google Patents

Polyribonucléotides circulaires et compositions pharmaceutiques associées

Info

Publication number
MA55206A
MA55206A MA055206A MA55206A MA55206A MA 55206 A MA55206 A MA 55206A MA 055206 A MA055206 A MA 055206A MA 55206 A MA55206 A MA 55206A MA 55206 A MA55206 A MA 55206A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
related pharmaceutical
circular polyribonucleotides
polyribonucleotides
circular
Prior art date
Application number
MA055206A
Other languages
English (en)
Inventor
Catherine Cifuentes-Rojas
Boer Alexandra Sophie De
Avak Kahvejian
Michael Donato Melfi
Ki Young Paek
Nicholas Mccartney Plugis
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA55206A publication Critical patent/MA55206A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055206A 2019-03-04 2020-03-04 Polyribonucléotides circulaires et compositions pharmaceutiques associées MA55206A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962813666P 2019-03-04 2019-03-04
US201962825683P 2019-03-28 2019-03-28
US201962840174P 2019-04-29 2019-04-29
US202062967545P 2020-01-29 2020-01-29

Publications (1)

Publication Number Publication Date
MA55206A true MA55206A (fr) 2022-01-12

Family

ID=70110338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055206A MA55206A (fr) 2019-03-04 2020-03-04 Polyribonucléotides circulaires et compositions pharmaceutiques associées

Country Status (10)

Country Link
US (1) US20220143062A1 (fr)
EP (1) EP3935162A1 (fr)
JP (2) JP2022523794A (fr)
KR (1) KR20210135265A (fr)
CN (3) CN121081491A (fr)
AU (1) AU2020233404A1 (fr)
CA (1) CA3128626A1 (fr)
IL (1) IL285906A (fr)
MA (1) MA55206A (fr)
WO (1) WO2020181013A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222911A1 (fr) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Arn circulaires et leur utilisation dans l'immunomodulation
MX2020006150A (es) 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
JP7618577B2 (ja) 2019-03-25 2025-01-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
US12636369B2 (en) 2019-06-19 2026-05-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
AU2022221309A1 (en) * 2021-02-09 2023-08-24 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
TW202300650A (zh) * 2021-03-26 2023-01-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 真核系統中環狀多核糖核苷酸的產生
AR125216A1 (es) * 2021-03-26 2023-06-28 Flagship Pioneering Innovations Vii Llc Producción de polirribonucleótidos circulares en un sistema eucariota
US20250188505A1 (en) * 2021-03-26 2025-06-12 Flagship Pioneering Innovations Vii, Llc Production of circular polyribonucleotides in a prokaryotic system
WO2022216977A1 (fr) 2021-04-07 2022-10-13 Batelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
EP4341423A1 (fr) * 2021-05-18 2024-03-27 Flagship Pioneering Innovations VI, LLC Procédés d'enrichissement de polyribonucléotides circulaires
JP2024521304A (ja) * 2021-05-18 2024-05-31 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを濃縮する方法
KR20240047986A (ko) 2021-07-27 2024-04-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 가공을 위한 디바이스, 시스템 및 방법
AU2022332372B2 (en) 2021-08-27 2025-12-04 Peking University Constructs and methods for preparing circular rna
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
EP4422698A1 (fr) * 2021-10-29 2024-09-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
KR102488280B1 (ko) * 2021-11-25 2023-01-16 주식회사 뉴클릭스바이오 신규한 부목 dna 및 이의 용도
CN114317684B (zh) * 2021-12-15 2023-12-26 南京大学 一种基于tna分子的细胞内镁离子成像的方法
CN118510896A (zh) 2021-12-17 2024-08-16 旗舰创业创新六公司 用于在变性条件下富集环状rna的方法
CN118451182A (zh) * 2022-01-28 2024-08-06 北京昌平实验室 环状rna疫苗及其使用方法
EP4612296A1 (fr) * 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
EP4648794A2 (fr) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccins et procédés associés
JP2026503676A (ja) 2023-01-27 2026-01-29 セイル バイオメディシンズ インコーポレイテッド 修飾脂質組成物およびその使用
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
CN116286916B (zh) * 2023-02-24 2025-08-22 北京大学人民医院 一种改良的i型内含子核酶序列用于构建环状rna的方法及应用
CN116466078B (zh) * 2023-03-07 2026-07-17 杭州西弗莱生物技术有限公司 抗mda5抗体的检测试剂盒及其制备方法
TW202517783A (zh) * 2023-06-28 2025-05-01 香港商瑞毅生物科技（香港）有限公司 工程化的rna多核苷酸及其製備方法
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
CN122249558A (zh) * 2023-10-24 2026-06-19 上海圆因生物科技有限公司 编码glp-1的环状rna及其用途
WO2025106930A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 2 de type glucagon (glp-2) et leurs utilisations
WO2025106915A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 1 de type glucagon (glp-1) et leurs utilisations
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025179198A1 (fr) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Polyribonucléotides circulaires et arn linéaires non modifiés à immunogénicité réduite
WO2025227064A1 (fr) * 2024-04-26 2025-10-30 Renasci Biotechnologies, Inc. Méthodes d'édition génomique pour le traitement d'une maladie cardiovasculaire et compositions destinées à être utilisées dans la mise en œuvre de celles-ci
WO2025240369A2 (fr) * 2024-05-13 2025-11-20 Helix Nanotechnologies Inc Procédés de distribution de polyribonucléotides nus
TW202613158A (zh) 2024-05-16 2026-04-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025245111A1 (fr) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Protéines de ciblage d'immunorécepteurs et procédés associés
CN118581085A (zh) * 2024-05-24 2024-09-03 国家纳米科学中心 一种翻译调控元件、表达载体、药物组合物、疫苗组合物、构建方法、表达目的蛋白的方法及应用
CN118688370B (zh) * 2024-08-27 2024-12-13 天津辰欣药物研究有限公司 一种抗病毒新药中间体的质量控制方法
WO2026096919A1 (fr) 2024-11-01 2026-05-07 Sail Biomedicines, Inc. Nouveaux lipides à cœur dipeptidique, vecteurs lipidiques et méthodes d'utilisation de ceux-ci
WO2026122747A2 (fr) 2024-12-05 2026-06-11 Flagship Pioneering Innovations Vii, Llc Nouvelles protéines immunomodulatrices et méthodes associées

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
AU683011B2 (en) 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
EP2428570B1 (fr) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de micro arn
WO2005013901A2 (fr) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
JP5296328B2 (ja) * 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2013070324A1 (fr) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Compositions de microvésicules dérivées de plante comestible pour le diagnostic et le traitement d'une maladie
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
AU2015289656A1 (en) * 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016183482A1 (fr) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Agents thérapeutiques d'un complexe membrane-récepteur
EP3303377B1 (fr) 2015-06-05 2022-11-23 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour thérapie génique transitoire à stabilité améliorée
CN107920995A (zh) 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
BR112019011138A2 (pt) 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
MX2020006150A (es) * 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
AR116016A1 (es) 2018-08-24 2021-03-25 Flagship Pioneering Innovations Vi Llc Métodos para fabricar paquetes mensajeros vegetales

Also Published As

Publication number Publication date
CN121081490A (zh) 2025-12-09
EP3935162A1 (fr) 2022-01-12
US20220143062A1 (en) 2022-05-12
WO2020181013A1 (fr) 2020-09-10
IL285906A (en) 2021-10-31
CN121081491A (zh) 2025-12-09
KR20210135265A (ko) 2021-11-12
JP2025090772A (ja) 2025-06-17
JP2022523794A (ja) 2022-04-26
CA3128626A1 (fr) 2020-09-10
AU2020233404A1 (en) 2021-09-16
CN113544269A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3891149A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3891148A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3436482A4 (fr) Anticorps, compositions pharmaceutiques et procédés
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
EP3603620A4 (fr) Composition de liposome et composition pharmaceutique
EP3541385A4 (fr) Formulations pharmaceutiques
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
MA55015A (fr) Formulations pharmaceutiques
EP3914234A4 (fr) Compositions pharmaceutiques
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
EP3773654A4 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
MA47516A (fr) Composition pharmaceutique
MA49837A (fr) Compositions pharmaceutiques
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
DK3908321T3 (da) Farmaceutisk sammensætning
EP3849523A4 (fr) Compositions pharmaceutiques ophtalmiques à libération prolongée et utilisations associées
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
EP3705122A4 (fr) Composition pharmaceutique à libération prolongée
EP3646863A4 (fr) Composition pharmaceutique